NEOSTIGMINE OMEGA DIN 02230593
Status: Marketed
Holder: OMEGA LABORATORIES LIMITED
Molecule: NEOSTIGMINE METHYLSULFATE
Available to quote
Health Canada record
| Active ingredient(s) | NEOSTIGMINE METHYLSULFATE 0.5 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intravenous; Subcutaneous; Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N07AA01 NEOSTIGMINE |
| Original market date | 28-May-1999 |
| Current status date | 23-Jul-1999 |
| Source | Health Canada DPD |
Establishment licence of the holder
Omega Laboratories Ltd. (now Juno Pharma Canada Inc.) — licence 100277, not currently licensed, last inspection rating C (2025-05-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NEOSTIGMINE METHYLSULFATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02475499 | NEOSTIGMINE METHYLSULFATE INJECTION USP | MARCAN PHARMACEUTICALS INC | Solution | NEOSTIGMINE METHYLSULFATE 1 MG | Marketed |
| 02497786 | NEOSTIGMINE METHYLSULFATE INJECTION USP | STERIMAX INC | Solution | NEOSTIGMINE METHYLSULFATE 1 MG | Approved |
| 02497778 | NEOSTIGMINE METHYLSULFATE INJECTION USP | STERIMAX INC | Solution | NEOSTIGMINE METHYLSULFATE 0.5 MG | Approved |
| 02475480 | NEOSTIGMINE METHYLSULFATE INJECTION USP | MARCAN PHARMACEUTICALS INC | Solution | NEOSTIGMINE METHYLSULFATE 0.5 MG | Marketed |
| 02537516 | NEOSTIGMINE METHYLSULFATE INJECTION, USP | JAMP PHARMA CORPORATION | Solution | NEOSTIGMINE METHYLSULFATE 0.5 MG | Marketed |
| 02230592 | NEOSTIGMINE OMEGA | OMEGA LABORATORIES LIMITED | Liquid | NEOSTIGMINE METHYLSULFATE 1 MG | Marketed |
| 02387166 | NEOSTIGMINE OMEGA | OMEGA LABORATORIES LIMITED | Solution | NEOSTIGMINE METHYLSULFATE 2.5 MG | Marketed |
| 01914588 | NEOSTIGMINE METHYLSULFATE INJ 1MG/ML USP | DAVID BULL LABORATORIES (PTY) LTD. | Liquid | NEOSTIGMINE METHYLSULFATE 1 MG | Cancelled Post Market |
| 02243103 | NEOSTIGMINE METHYLSULFATE INJECTION | FRESENIUS KABI CANADA LTD | Liquid | NEOSTIGMINE METHYLSULFATE 1 MG | Cancelled Pre Market |
| 02243104 | NEOSTIGMINE METHYLSULFATE INJECTION | FRESENIUS KABI CANADA LTD | Liquid | NEOSTIGMINE METHYLSULFATE 0.5 MG | Cancelled Pre Market |
| 02385201 | NEOSTIGMINE METHYLSULFATE INJECTION SDZ | SANDOZ CANADA INCORPORATED | Solution | NEOSTIGMINE METHYLSULFATE 0.5 MG | Cancelled Pre Market |
| 02385228 | NEOSTIGMINE METHYLSULFATE INJECTION SDZ | SANDOZ CANADA INCORPORATED | Solution | NEOSTIGMINE METHYLSULFATE 2.5 MG | Cancelled Pre Market |
| 00885282 | NEOSTIGMINE METHYLSULFATE INJECTION USP | SANDOZ CANADA INCORPORATED | Liquid | NEOSTIGMINE METHYLSULFATE 1 MG | Cancelled Post Market |
| 01915436 | NEOSTIGMINE METHYLSULFATE INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | NEOSTIGMINE METHYLSULFATE 2.5 MG | Cancelled Post Market |
| 00874957 | NEOSTIGMINE METHYLSULFATE INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | NEOSTIGMINE METHYLSULFATE 0.5 MG | Cancelled Post Market |
| 02546191 | NEOSTIGMINE METHYLSULFATE INJECTION, USP | JUNO PHARMACEUTICALS CORP. | Solution | NEOSTIGMINE METHYLSULFATE 2.5 MG | Cancelled Pre Market |
| 02546175 | NEOSTIGMINE METHYLSULFATE INJECTION, USP | JUNO PHARMACEUTICALS CORP. | Solution | NEOSTIGMINE METHYLSULFATE 0.5 MG | Cancelled Pre Market |
| 02546183 | NEOSTIGMINE METHYLSULFATE INJECTION, USP | JUNO PHARMACEUTICALS CORP. | Solution | NEOSTIGMINE METHYLSULFATE 1 MG | Cancelled Pre Market |
| 00868930 | PMS-NEOSTIGMINE METHYLSULFATE INJ 1MG/ML | PHARMASCIENCE INC | Liquid | NEOSTIGMINE METHYLSULFATE 1 MG | Cancelled Post Market |
| 00869929 | PROSTIGMIN INJ 1:1000 USP | ICN CANADA LTD. | Liquid | NEOSTIGMINE METHYLSULFATE 1 MG | Cancelled Post Market |
| 00869937 | PROSTIGMIN INJ 1:400 USP | ICN CANADA LTD. | Solution | NEOSTIGMINE METHYLSULFATE 2.5 MG | Cancelled Post Market |
| 00564508 | STIMULINE INJ 2MG/ML | DISTRIVET INC. | Liquid | NEOSTIGMINE METHYLSULFATE 2 MG | Cancelled Post Market |
International API supply for NEOSTIGMINE METHYLSULFATE
9 active FDA Drug Master Files.
Request a quote for NEOSTIGMINE OMEGA